Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch
By Christine Filippis / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
By Christine Filippis / November 8, 2022
Melbourne, Victoria, Australia - 08 November 2022 The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced...
Read More
Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research
By Christine Filippis / October 17, 2022
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for...
Read More
